Lyra Therapeutics, Inc. (LYRA) earnings
LYRA earnings moved a median of +0.02% by the close. Quarterly and annual LYRA reports and results, each read against the price at its own news timestamp. Back to the LYRA overview →
17 measured LYRA earnings events.
Where these LYRA earnings landedvs 15 measured LYRA earnings reactions
| Middle 50% of LYRA earnings reactions | -4.11% to +2.63% |
|---|---|
| Median reaction (to close) | +0.02% |
| Measured reactions | 15 |
Point-in-time · zero look-ahead
Half of the 15 LYRA earnings events with a measured close landed between -4.11% and +2.63%; 53% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-K Lyra Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +0.02% | |
| Form 10-Q Lyra Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.68% | — | |
| Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -1.68% | — | |
| Form 10-Q Lyra Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +6.11% | |
| Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | +6.11% | |
| Form 10-Q Lyra Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.09% | -4.11% | |
| Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | -0.09% | -4.11% | |
| Form 10-K Lyra Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.59% | +0.88% | |
| Form 10-Q Lyra Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.21% | -25.40% | |
| Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -1.21% | -25.40% | |
| Form 10-Q Lyra Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.63% | +0.66% | |
| Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +1.63% | +0.66% | |
| Form 10-Q Lyra Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.39% | +4.37% | |
| Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +2.39% | +4.37% | |
| Form 10-K Lyra Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -7.60% | -7.00% | |
| Form 10-Q Lyra Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -4.67% | -2.33% | |
| Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | -4.67% | -2.33% |
Keep exploring
More LYRA: analyst actions → · SEC filings → · LYRA overview →